p110

Dynamin-related protein 1 (Drp1) inhibitor, inhibits Drp1 GTPase activity. Displays no effect on dynamin 1 or other mitochondrial dynamics-related proteins. Inhibits mitochondrial fission, dysfunction and reactive oxygen species (ROS) production in vitro.

P110 TFA is a dynamin-related protein 1 (Drp1) inhibitor, inhibits Drp1 GTPase activity.

TAT-P110 is a peptide inhibitor that disrupts the interaction between Drp1 and Fis1, effectively reducing pathological changes in various models of neurodegenerative diseases, ischemia, and sepsis without impairing the physiological function of Drp1.

Compound P110 (Drp1 peptide inhibitor P110) is a selective Drp1 peptide inhibitor with neuroprotective effects. It inhibits the activation of Drp1, prevents Drp1 mitochondrial translocation induced by MPTP, and alleviates dopamine neuron loss, dopaminergic terminal damage, and behavioral deficits caused by MPTP. This compound is useful for Alzheimer's disease research. Additionally, Compound P110 reduces mitochondrial and organ damage in animal models of Huntington's disease, cerebral ischemia, and myocardial infarction.

P110δ-IN-1 (PWT-143) is an effective and selective inhibitor of P110δ (IC50: 8.4 nM).

Row174336 (compound 29) serves as an efficient inhibitor of the Hsp110-STAT3 interaction, exhibiting antiproliferative activity in the HPAEC cell line with an IC50 of 22.67 μM.

Hsp110-STAT3 interaction-IN-2 (compound 10b) is an inhibitor of the Hsp110-STAT3 interaction. It is utilized in research related to pulmonary arterial hypertension (PAH).

iHSP110-33 is an inhibitor of the molecular chaperone heat shock protein 110 (HSP110). This compound exhibits antitumor effects against large B-cell lymphoma and classical Hodgkin's lymphoma. It works synergistically with Selinexor, enhancing the inhibition of STAT6 phosphorylation and boosting its antitumor activity.

MCP110 is an inhibitor of the interaction of Ras with Raf-1 and can be used in studies about the treatment of human tumors.

Hsp110/sGC-modulator-1 (compound 17i) is a dual-target modulator of Hsp110 and sGC with oral activity, exhibiting optimal molecular activity against both Hsp110 and sGC targets. Additionally, it demonstrates significant inhibitory effects on malignant cellular phenotypes and vasodilation. Hsp110/sGC-modulator-1 (compound 17i) alleviates pulmonary vascular remodeling and right ventricular hypertrophy by inhibiting Hsp110.

LY294002 (SF 1101) is a broad-spectrum inhibitor of PI3K, inhibiting PI3Kα, PI3Kδ, and PI3Kβ (IC50=0.5/0.57/0.97 μM). LY294002 is also an inhibitor of DNA-PK (IC50=1.4 μM) and an inhibitor of CK2 (IC50=98 nM). LY294002 activates apoptosis and autophagy.

Torin 1 is an effective inhibitor of mTORC1/2 with (IC50: 2 nM/10 nM); has 1000-fold selectivity for mTOR than PI3K.

Duvelisib (INK1197, IPI-145) is a selective inhibitor of phosphatidylinositol 3-kinase (PI3K) and p100δ, with effects on p110δ (IC50 value is 0.0025 μM), p110γ (IC50 value is 0.274 μM), p110β (IC50 value is 0.85 μM) and p110α (IC50 value is 1.602 μM).

TGX-115 is a cell-permeable and potent inhibitor of the PI 3-K isoform p110β/p110δ (IC50 values of 0.13 μM for p110β and 0.63 μM for p110δ), an enzyme that regulates platelet adhesion and inhibits phosphoinositide (PI) 3-kinase, and can be used to treat coronary artery occlusion, stroke, acute coronary artery It can be used to treat cardiovascular diseases such as coronary occlusion, stroke, acute coronary syndrome, acute myocardial infarction, restenosis, atherosclerosis and unstable angina.

Idelalisib (GS-1101) is a small molecule inhibitor of the PI3K catalytic subunit p110δ (IC50: 2.5 nM). The selectivity for p110δ is 40- to 300-fold than p110α/β/γ.

Alpelisib (BYL-719) is a PI3Kα inhibitor (IC50=5 nM) with selective, potent, and oral activity, inhibiting PI3Kβ/γ/δ with low activity (IC50=250/290/1200 nM). Alpelisib demonstrates antitumor activity and specifically targets PIK3CA mutant tumors.

PI-3065 is a novel potent and selective PI3K p110δ inhibitor.

Acalisib (CAL-120) (GS-9820) is a potent and selective inhibitor of PI3Kδ.

Melanin Concentrating Hormone, salmon acetate (MCH (salmon)) is a 19 amino acid cyclic peptide, is largely expressed in the hypothalamus.

ETP-46321 is an effective and orally bioavailable PI3Kα/PI3Kδ inhibitor (Ki: 2.3/14.2 nM).

CAL-130 is a PI3Kδ and PI3Kγ inhibitor [IC50s: 1.3 and 6.1 nM].

CAL-130 Hydrochloride is a PI3Kδ and PI3Kγ inhibitor (IC50s: 1.3 and 6.1 nM).

Pictilisib dimethanesulfonate (GDC-0941 2 MeSO3H salt) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).

Idelalisib D5, a version of Idelalisib marked with deuterium, is an orally bioavailable and highly selective inhibitor of p110δ.